L

    Lifecore Biomedical Inc. (LFCR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $4.46
    -0.08 (-1.76%)

    Market Cap: $171.85M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -135.40%
    Streak
    1 Q

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-0.29
    Range$-0.33 - $-0.24
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate Drift
    90d ago$-0.25+12.9%
    60d ago$-0.25+12.9%
    30d ago$-0.29+0.0%
    7d ago$-0.29+0.0%
    Current$-0.29
    Revenue Consensus
    $26M
    Range$25M - $27M
    5 analysts
    Jun 30, 2026
    EPS Consensus$-0.22
    Range$-0.30 - $-0.17
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.21+4.5%
    60d ago$-0.22+0.0%
    30d ago$-0.22+0.0%
    7d ago$-0.22+0.0%
    Current$-0.22
    Revenue Consensus
    $32M
    Range$31M - $33M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    May 27EST
    		-$0.07---
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.30---
    Jun 26EST
    		-$-0.22---
    Mar 26EST
    		-$-0.29---
    Aug 26
    		$-0.19$-0.22+14.61%Beat+55.8%
    May 26
    		$-0.19$-0.17-11.76%Miss-90.0%
    Feb 26
    		$-0.16$-0.23+30.43%Beat+66.0%
    Nov 25
    		$0.00N/A+100.00%Beat+100.0%
    Aug 25
    		$-0.43$-0.30-43.33%Miss-16.2%
    May 25
    		$-0.10$-0.09-11.11%Miss+41.2%
    Feb 25
    		$-0.47$-0.15-213.33%Miss-211.9%
    Nov 24
    		$-0.20$-0.30+33.33%Beat-53.8%
    Aug 24
    		$-0.37$-0.46+19.57%Beat+69.0%
    May 24
    		$-0.17$-0.12-41.67%Miss-54.5%
    Feb 24
    		$0.42$0.13+223.08%Beat+200.0%
    Nov 23
    		$-0.13$-0.23+43.48%Beat+38.1%
    Aug 23
    		$-1.19$-0.23-418.13%Miss-272.4%
    May 23
    		$-0.11$-0.07-57.14%Miss-1000.0%
    Feb 23
    		$-0.42$-0.11-281.82%Miss-425.0%
    Nov 22
    		$-0.21$-0.04-425.00%Miss+4.5%
    Aug 22
    		$-0.32$-0.13-146.15%Miss-39.1%
    May 22
    		$-0.01$-0.01+0.00%Beat-114.3%
    Feb 22
    		$-0.08$-0.03-166.67%Miss+57.9%
    Nov 21
    		$-0.22$-0.09-144.44%Miss-1200.0%
    Aug 21
    		$-0.23$-0.12-91.67%Miss+39.5%
    May 21
    		$0.07$-0.01+800.00%Beat+40.0%
    Feb 21
    		$-0.19$0.04-575.00%Miss+51.3%
    Nov 20
    		$0.02$0.03-33.33%Miss+112.5%
    Aug 20
    		$-0.38$-0.13-192.31%Miss-137.5%
    May 20
    		$0.05$0.03+66.67%Beat+600.0%
    Feb 20
    		$-0.39$-0.01-3800.00%Miss-1075.0%
    Nov 19
    		$-0.16$-0.06-166.67%Miss-700.0%
    Aug 19
    		$-0.16$-0.16+0.00%Beat-1700.0%
    May 19
    		$-0.01$-0.02+50.00%Beat-104.2%
    Feb 19
    		$0.04$0.05-20.00%Miss-55.6%
    Nov 18
    		$-0.02$-0.02+0.00%Beat-200.0%
    Aug 18
    		$0.01N/A-83.33%Miss-87.5%
    May 18
    		$0.24$0.22+9.09%Beat+166.7%
    Feb 18
    		$0.09$0.09+0.00%Beat-50.0%
    Nov 17
    		$0.02$0.01+100.00%Beat-60.0%
    Aug 17
    		$0.08$0.06+33.33%Beat-
    May 17
    		$0.09$0.09+0.00%Beat-
    Feb 17
    		$0.18$0.18+0.00%Beat-
    Nov 16
    		$0.05$0.06-16.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.60EV/EBITDA8.11x
    Price/FCF21.67xFCF Yield4.61%
    Profitability
    Profit Margin-23.80%Operating Margin7.51%
    ROE-76.40%ROIC-5.76%
    Financial Health
    Debt/Equity6.88xInterest Coverage-0.33x
    Current Ratio3.79xQuick Ratio2.41x
    Trading Statistics
    Beta1.09Avg Volume122.11K
    52-Week High$8.9852-Week Low$3.63

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.53
    SMA 20$4.61
    SMA 50$4.74
    SMA 200$6.00
    EMA 10$4.55
    EMA 20$4.58
    EMA 50$4.72
    EMA 200$5.58

    MACD

    Line: -0.05Signal: -0.05Hist: 0.00

    ADX

    ADX: 10.4+DI: 19.1-DI: 19.4

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down28.0
    PSAR$4.82

    Bollinger Bands

    Upper Band$4.95
    Lower Band$4.27
    %B Position1469%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    43.6

    Momentum Oscillators

    Stoch %K29.7
    Stoch %D36.7
    Williams %R-77.9
    ROC (10d)-1.8%
    Momentum-0.08
    CCI (20d)-61.4
    MFI (14d)21.2

    Volatility Measures

    ATR (14d)$0.24(5.4%)
    StdDev (20d)0.17
    Hist Vol52.5%(High)

    Volume Flow

    VWAP$4.50
    OBV-2.1M
    AD Line-2.7M
    CMF (20d)-0.018

    Volume Metrics

    Avg Vol (20d)121.6K
    Vol Ratio0.7x
    VWMA (20d)$4.63

    Pivot Points

    R3$4.82
    R2$4.73
    R1$4.64
    Pivot Point$4.55
    S1$4.46
    S2$4.37
    S3$4.28

    Advanced Oscillators

    TSI-6.35
    Ultimate Osc38.1
    KST-16.83

    Financial Data

    QuarterFeb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023Aug 2023May 2023
    Total Revenue$23.19M$34.17M$23.19M$36.44M$35.15M$36.44M$24.70M$37.88M$35.70M$30.15M$24.52M$31.14M
    Cost of Revenue$18.73M$22.09M$18.73M$22.46M$25.31M$22.46M$19.32M$20.61M$23.81M$20.19M$21.79M$23.37M
    Gross Profit$4.46M$12.07M$4.46M$13.98M$9.85M$13.98M$5.39M$17.27M$11.89M$9.96M$2.73M$7.78M
    Operating Expenses$9.13M$9.51M$9.13M$8.65M$18.87M$8.65M$16.97M$15.12M$12.79M$11.44M$11.34M$14.42M
    R&D$1.22M$1.54M$1.22M$2.10M$2.04M$2.10M$2.19M$2.16M$2.17M$2.10M$2.15M$2.11M
    SG&A$7.92M$7.97M$7.92M$8.05M$9.98M$8.98M$14.79M$12.08M$9.85M$9.34M$9.20M$12.30M
    Operating Income$-4,672,000$2.57M$-4,672,000$5.33M$-9,029,000$5.33M$-11,584,000$2.15M$-895,000$-1,483,000$-8,614,000$-6,639,000
    Interest Income$128,000$144,000$128,000$0$108,000$206,000$15,000$0$-4,289,000$0$0$0
    Interest Expense$7.35M$7.75M$7.35M$6.44M$5.59M$5.73M$5.38M$9.29M$0$4.07M$3.94M$29.65M
    Income Before Tax$-14,937,000$-6,133,000$-14,937,000$-1,114,000$-14,777,000$-1,114,000$-16,255,000$-7,143,000$15.00M$14.18M$-12,522,000$-36,768,000
    Income Tax Expense$43,000$23,000$43,000$33,000$-8,000$33,000$-25,000$-57,000$217,000$-65,000$88,000$230,000
    Net Income$-14,980,000$-6,156,000$-14,980,000$-1,147,000$-14,769,000$-1,147,000$-16,230,000$-7,083,000$15.63M$14.22M$-10,754,000$-39,284,000
    EBITDA$-5,279,000$3.99M$-5,407,000$6.32M$-7,220,000$6.40M$-8,894,000$661,000$21.30M$20.02M$-6,416,000$-4,448,000
    EBIT$-7,589,000$1.47M$-7,717,000$4.41M$-9,296,000$4.41M$-10,887,000$-1,353,000$19.29M$18.25M$-8,584,000$-7,118,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LFCR

    News

    LFCR | Lifecore Biomedical, Inc. Common Financials - Revenue Breakdown

    This article provides a financial overview of Lifecore Biomedical, Inc. (LFCR), focusing on its revenue breakdown, though specific segment and geographic revenue data are noted as unavailable. It details various financial aspects including insider trading, institutional holdings, analyst ratings, and executive compensation, emphasizing the company's role as a CDMO in sterile injectable pharmaceutical products. The page also features a "Smart Score" and "Bull Case vs. Bear Case" analysis, accessible to premium subscribers.

    Quiver Quantitative•8/23/26•
    Neutral

    Judge approves $3.75 million Lifecore investor settlement

    A federal judge has granted final approval for a $3.75 million settlement in a securities class action lawsuit against Lifecore Biomedical Inc. Investors accused Lifecore of making false statements about its financial condition and internal accounting controls, which led to a stock price drop after disclosures of material weaknesses. The settlement, which represents about 5.3% of estimated maximum damages, also includes approximately $1.25 million in attorneys' fees.

    Minnesota Lawyer•8/12/26•
    Somewhat-Bearish

    Press Release: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

    Lifecore Biomedical announced its financial results for the second quarter ended June 30, 2026, including key revenue and earnings figures. The company also provided a corporate update, likely detailing strategic initiatives, pipeline progress, or other business developments. This release offers insight into Lifecore's recent financial performance and current operational status.

    Moomoo•8/6/26•
    Bullish

    Lifecore Biomedical Releases Q2 2026 Financial Results

    Lifecore Biomedical, Inc. (LFCR) reported its Q2 2026 financial results, narrowing its loss per share to -$0.19 and exceeding revenue expectations with $34.2 million. Despite beating estimates, the company experienced a 6.2% revenue decline year-over-year due to softness in its CDMO segment. Management provided full-year revenue guidance of $120.0M to $125.0M as they work to stabilize operations and expand their customer base.

    AlphaStreet•8/6/26•
    Neutral

    Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

    Lifecore Biomedical (NASDAQ:LFCR) reported its quarterly earnings, exceeding analyst estimates with an EPS loss of $0.19, $0.03 better than expected, and revenue of $34.17 million, surpassing the $32.02 million forecast. Despite a year-to-date revenue decline and widened net loss, the company reaffirmed its 2026 revenue and adjusted EBITDA guidance, anticipating stronger contract development and manufacturing revenue in the second half of the year. Institutional investors have been actively trading LFCR shares, and analysts currently rate the stock as "Hold" with a consensus target price of $6.50.

    MarketBeat•8/6/26•
    Somewhat-Bullish

    Frequently Asked Questions About LFCR

    Does LFCR pay dividends?
    Lifecore Biomedical Inc. (LFCR) does not currently pay a regular dividend.
    What is LFCR's market cap?
    Lifecore Biomedical Inc. (LFCR) has a market capitalization of $171.85M with a current stock price of $4.46.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In